The organ preservation market encompasses the medical and pharmaceutical sector focused on storing, maintaining, and transporting donated organs in optimal conditions outside the body to sustain their viability before transplantation. It includes preservation solutions, machine perfusion systems, and cold-chain devices used for both intraabdominal and intrathoracic organs.
The global organ preservation market was valued at USD 0.1 billion in 2024 and reached USD 0.2 billion in 2025. It is projected to grow at a robust compound annual growth rate (CAGR) of 6.8%, hitting USD 0.3 billion by 2030.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=261269915
The organ preservation market is primarily driven by the escalating global prevalence of chronic diseases and organ failures, alongside an increasing volume of organ transplant procedures and continuous innovations in advanced perfusion technologies. However, market expansion is heavily restrained by the high upfront costs of advanced capital equipment like machine perfusion systems, expensive specialized solutions, and steep overall transplantation costs that limit patient accessibility. Lucrative opportunities lie in the integration of technological advancements such as artificial intelligence, robotics, and bioengineering to optimize organ viability, coupled with increasing global healthcare investments and expanding applications for complex oncology treatments. Despite these prospects, the market faces critical challenges, including severe donor organ shortages that create a persistent gap between supply and demand, stringent regulatory frameworks and compliance hurdles that delay product launches, and logistical limitations like a lack of skilled professionals or cryogenic transportation networks in resource-constrained regions.
The target customers for the organ preservation industry market primarily encompass healthcare providers, including hospitals, dedicated organ transplant centers, and specialty clinics, with organ transplant centers and hospitals commanding the largest shares due to concentrated surgical volumes. These institutional buyers need highly effective preservation techniques, solutions, and advanced machine perfusion technologies to minimize ischemic damage, extend donor organ viability during storage or transport, and reduce high organ discard rates driven by a persistent global shortage of donor organs. They strongly prefer solutions with broad clinical validation, such as the gold-standard University of Wisconsin solution, as well as innovative, tech-enabled systems integrated with IoT and remote monitoring for real-time tracking of organ conditions. Their purchasing behavior is defined by direct procurement relationships with solution suppliers and medical device manufacturers, procedurally mandated utilization aligned with transplant surgery volumes, and a growing willingness to commit higher per-procedure spend toward advanced hypothermic or normothermic machine perfusion technologies that optimize clinical outcomes.
Market entry, expansion, and profitability in the organ preservation industry market are heavily influenced by shifting regulatory landscapes, technological innovations, and economic pressures. Regulators shape the market through strict compliance standards, deliberate and methodical device approval pathways, and emerging regulatory uncertainties for novel normothermic perfusion technologies, alongside modernizing frameworks that expand transplant program capacities. Technologically, the industry is being disrupted by the rapid adoption of advanced machine perfusion systems—such as normothermic and hypothermic machine perfusion—advanced cold-chain transport devices equipped with real-time GPS and temperature tracking, and the emergence of AI-driven organ viability analytics for marginal donors. Economically, the market faces strong restraints from the high capital and operating costs of preservation devices and specialized single-use perfusion sets, limited or uneven insurance reimbursement policies, and supply-chain constraints for proprietary solutions, though profitability is increasingly supported by new reimbursement codes covering ex-vivo perfusion disposables and the shift toward software-embedded recurring-income ecosystems.
The organ preservation market is being significantly shaped by a pivotal technological transition from traditional static cold storage to advanced machine perfusion systems, particularly normothermic machine perfusion (NMP) and hypothermic machine perfusion (HMP). These emerging techniques enable real-time organ assessment, metabolic reconditioning, and extended preservation times, effectively expanding the usable donor organ pool. Additional prominent trends include the growing integration of artificial intelligence for automated viability assessments, digital tracking to secure cold-chain logistics, and continuous updates to specialized preservation solutions aimed at reducing ischemic injury. These innovations are evolving rapidly, as evidenced by a substantial shift in standard clinical protocols driven by recent FDA clearances for portable perfusion systems and double-digit growth rates in key segments; for instance, the normothermic machine perfusion segment is projected to expand at a swift compound annual growth rate (CAGR) of 10.31% through 2031, outstripping baseline industry growth as healthcare providers increasingly prioritize improved graft utilization and superior patient survival outcomes.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=261269915
Technological innovations disrupting the organ preservation industry are centered on shifting from traditional static cold storage to advanced machine perfusion systems, which significantly improve organ viability and extend storage timelines. The market is witnessing rapid adoption of hypothermic and normothermic machine perfusion technologies, such as the OrganOx metra system, which circulate oxygenated fluids or blood to maintain physiological function and reduce delayed graft function. Additionally, innovations include the integration of remote monitoring dashboards that allow clinicians to review real-time organ data simultaneously, FAA-compliant portable transport devices for safer long-distance logistics, and the development of specialized additive solutions, like the marine-worm-derived hemoglobin HEMO2life, to enhance tissue oxygenation and minimize cellular swelling.
In the organ preservation industry market, short-term trends and hype are characterized by early-stage, completely non-invasive optical tracking concepts and intensive social media promotions for consumer wellness or generic testing kits that often outpace clinical reliability. Conversely, long-term structural shifts are firmly anchored in the industry’s transition from passive static cold storage to active physiological machine perfusion, moving the sector from a preservation-only model to an organ-optimization model. These permanent transformations include the rising clinical adoption of normothermic and hypothermic machine perfusion platforms that enable real-time metabolic monitoring, the integration of advanced sensors and automated data-driven systems, and major strategic consolidations among med-tech conglomerates seeking to expand the usable donor organ pool and enhance transplant success rates.
Source:https://www.marketsandmarkets.com/Market-Reports/organ-preservation-market-261269915.html
